Leland Stanford Junior University, or more commonly Stanford University, is a private research university in Stanford, California, and one of the world's most prestigious institutions, with the highest undergraduate selectivity and the top position in numerous surveys and measures in the United States.Stanford was founded in 1885 by Leland Stanford, former governor of and U.S. senator from California and leading railroad tycoon, and his wife, Jane Lathrop Stanford, in memory of their only child, Leland Stanford, Jr., who had died of typhoid fever at age 15 the previous year. Stanford was opened on October 1, 1891 as a coeducational and non-denominational institution. Tuition was free until 1920. The university struggled financially after Leland Stanford's 1893 death and after much of the campus was damaged by the 1906 San Francisco earthquake. Following World War II, Provost Frederick Terman supported faculty and graduates' entrepreneurialism to build self-sufficient local industry in what would later be known as Silicon Valley. By 1970, Stanford was home to a linear accelerator, and was one of the original four ARPANET nodes .Stanford is located in northern Silicon Valley near Palo Alto, California. The University's academic departments are organized into seven schools, with several other holdings, such as laboratories and nature reserves, located outside the main campus. Its 8,180-acre campus is one of the largest in the United States. The University is also one of the top fundraising institutions in the country, becoming the first school to raise more than a billion dollars in a year.Stanford's undergraduate program is the most selective in the country with an acceptance rate of 5.07% for the 2018 Class. Students compete in 36 varsity sports, and the University is one of two private institutions in the Division I FBS Pacific-12 Conference. It has gained 105 NCAA team championships, the second-most for a university, 465 individual championships, the most in Division I, and has won the NACDA Directors' Cup, recognizing the university with the best overall athletic team achievement, every year since 1994-1995.Stanford faculty and alumni have founded many companies including Google, Hewlett-Packard, Nike, Sun Microsystems, and Yahoo!, and companies founded by Stanford alumni generate more than $2.7 trillion in annual revenue, equivalent to the 10th-largest economy in the world. Fifty-nine Nobel laureates have been affiliated with the University, and it is the alma mater of 30 living billionaires and 17 astronauts. Stanford has produced a total of 18 Turing Award laureates, the highest in the world for any one institution. It is also one of the leading producers of members of the United States Congress. Wikipedia.
Stanford University | Date: 2017-03-29
Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided
Stanford University | Date: 2017-02-16
A method of real-time radiotherapy beam visualization is provided that includes disposing a free-form flexible scintillating sheet on a subject of interest, irradiating the subject of interest with a source of ionizing radiation, where the free-forming flexible scintillating sheet emits light when irradiated by the therapeutic photon beam, collecting the emitted light and collecting ambient light reflected from the subject of interest and surrounding objects using a camera, where the collected light is converted to image data by the camera, where the image data is communicated to an appropriately programmed computer, and processing the image data to determine beam characteristics and the characteristics of the subject of interest, using the appropriately programmed computer, where the beam characteristics and the characteristics of the subject of interest are displayed in real-time to a machine operator enabling real-time verification of treatment delivery.
Stanford University | Date: 2017-06-21
Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
Stanford University | Date: 2017-02-06
Disclosed herein are systems and methods involving the use of magnetic resonance imaging and optogenetic neural stimulation. Aspects of the disclosure include modifying a target neural cell population in a first region of a brain to express light-responsive molecules. Using a light pulse, the light-responsive molecules in the target neural cell population are stimulated. Multiple regions of the brain are scanned via magnetic resonance imaging. The scans allow for observation of a neural reaction in response to the stimulation in at least one of the multiple regions of the brain.
Stanford University | Date: 2017-03-01
Compositions and methods are provided for inhibiting or treating the early and established stages of inflammatory diseases by administration of an effective dose of the desethylhydroxychloroquine (DHCQ). A benefit of the methods is the ability to deliver a dose of agent that is effective in treating inflammation while sparing the individual from retinal toxicity.
Vib Vzw, Vrije Universiteit Brussel and Stanford University | Date: 2017-01-18
The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.
Stanford University | Date: 2017-02-01
A 1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a 1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the 1-ADR agonist compound.
Stanford University | Date: 2017-05-24
A cathode for water splitting production includes: (1) a porous substrate; and (2) an electrocatalyst affixed to the porous substrate. The electrocatalyst includes heterostructures of a first material and a second material that partially covers the first material.
Stanford University | Date: 2017-07-05
The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.
Steinman L.,Stanford University
Annual Review of Immunology | Year: 2014
Eighty percent of individuals with multiple sclerosis (MS) initially develop a clinical pattern with periodic relapses followed by remissions, called relapsing-remitting MS (RRMS). This period of fluctuating disease may last for a decade or more. Clinical relapses reflect acute inflammation in the central nervous system (CNS), composed of the brain and spinal cord. Often, different anatomic areas in the CNS are involved each time a relapse occurs, resulting in varied clinical manifestations in each instance. Relapses are nearly always followed by some degree of remission, though recovery to baseline status before the flare is often incomplete. There are nine approved drugs for treatment of RRMS. The most potent drug for inhibiting relapses, the humanized anti-α4 integrin antibody known as Natalizumab, blocks homing of mononuclear cells to the CNS. The mechanisms of action of the approved drugs for RRMS provide a strong foundation for understanding the pathobiology of the relapse. Despite substantial progress in controlling relapses with the current armamentarium of medications, there is much to learn and ever more effective and safe therapies to develop. © 2014 by Annual Reviews. All rights reserved.